Research Type: Business and Popular Press

Our expertise and opinions regarding drug pricing and development are sought by journalists for both Business and Popular Press. Our editorial writings, often in collaboration with other experts, allows us to comment in a broader forum.

  • Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

  • Time to Throw in the Towel on Biosimilars

  • Mortgaging New Treatments Kicks the Can on High Drug Prices

  • Analysis of Medicare Part D Plans Shows $9B Upcharge

  • Fact Checking the NYT Fact Check on the Trump Proposal

  • DPL Policy Tracker Collects Drug Pricing Legislation and Proposals

  • A $475,000 price tag for a new cancer drug: crazy or meh?

  • Baseball Illuminates the Problem with U.S. Drug Pricing

    Baseball Illuminates the Problem with U.S. Drug Pricing

  • DPL and Collaborators to Publish Drug Pricing Primer Series

  • Is Outcomes-Based Contracting Worth It?